Astraveus develops Lakhesys, marketed as The Benchtop Cell Factory™, a compact platform using microfluidic technologies to produce hundreds of cell therapy doses per year. The company positions its instrument to improve quality and dramatically reduce manufacturing costs for cell therapies, facilitating scale-up from preclinical stages to commercial production. Astraveus emphasizes making these therapies more accessible and affordable worldwide. It was founded in 2016 by Jérémie Laurent at Hôpital Saint-Louis in Paris. The company intends to support commercialization and manufacturing capability expansion, including a new line of microfluidic consumables enabled by the recent public funding. The article does not disclose revenue, user, or other operating metrics.

Total raised

$37M

Funding rounds

3

Latest round

Grant

Latest activity

Oct 2023